About Us


Emendo was set up to expand what is possible in genome editing. We believe that challenges can be overcome by fusing expertise in diverse disciplines, and by looking at the core questions with a new approach. Having studied at top academic institutions, including the Weizmann Institute, Emendo’s founders came together to pool their collective knowledge of protein engineering and DNA repair to achieve a shared goal: the creation of genetic medicines that deliver on the promise of gene editing. By transforming the available tools, we are able to address those disorders and diseases that are currently considered to be untreatable. Working at the cutting edge of gene editing, the Emendo team combines knowledge, expertise and proven scientific methodologies, with creativity, ingenuity and daring to push the boundaries and achieve more.

Board Of Directors

Todd Wider, MD

Executive Chairman & CMO

Todd Wider, MD has served as a consultant to numerous entities in the biotechnology space.   He is an attending surgeon at Mount Sinai West in New York City.  Todd graduated from Princeton University, Phi Beta Kappa with High Honors, and received his MD from Columbia College of Physicians and Surgeons.  Todd completed his surgery and plastic and reconstructive surgery residencies at Columbia Presbyterian Hospital and did additional fellowships at Memorial Sloan Kettering and the University of Miami in complex oncologic microsurgery and craniofacial surgery.

Carl Gordon

Member of the Board

Carl L. Gordon, Ph.D., CFA, is a founding Partner and Co-Head of Global Private Equity at OrbiMed.  He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. For the last five years (2014 to 2018) Forbes® Magazine named Mr. Gordon one of the top 100 venture capitalists in the world when it placed him on the "Forbes Midas List". Carl received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology (1993) and a Bachelor of Arts Degree from Harvard College (1987).

Stephen Squinto, Ph.D.

Member of the Board

Stephen Squinto is a Venture Partner with OrbiMed who brings over 25 years of biotechnology industry experience.  Dr. Squinto was a co-founder of Alexion Pharmaceuticals, Inc. and recently served as its Executive Vice President and Chief Global Operations Officer.

Erez Chimovits

Member Of The Board

Erez Chimovits is a Senior Managing Director in Orbimed. Erez has 14 years of operational experience, including 10 years of senior managerial experience in public companies. Prior to joining OrbiMed Erez was the CEO of NasVax (TASE:NSVX).

Robbie Woodman, Ph.D.

Member Of The Board

Senior Partner, and is based in London, UK. Rob was Director of Investments at Touchstone Innovation and actively involved in numerous investments throughout EuropeRob holds an MSc in Biochemistry from the University of Oxford and a Ph.D. in Oncology from the University of Cambridge.

David Baram, Ph.D.

President & CEO

David has 14 years’ experience as an executive manager and entrepreneur. Former managing partner of Base Investments for five years, he has brought more than 20 products to market in the healthcare and cosmetics industries.


David Baram, Ph. D.

President & CEO

David has 10 years’ experience as an executive manager and entrepreneur. Former managing partner of Base Investments for the past five years, he has brought more than 20 products to market in the healthcare and cosmetics industries. Co-founder and member of the board of five biomed companies, inventor of drug development, discovery and delivery methodologies, David holds a PhD and MSc in Structural Biology from the Weizmann Institute of Science. He conducted his research under the Nobel Laureate Professor Ada Yonath.

Lior Izhar, Ph. D.

Chief Biologist

With over 10 years of research experience in the field of DNA damage and repair, Lior holds a PhD in molecular biology from the Weizmann Institute of Science prior to joining Emendo, he completed his postdoctoral fellowship at the Steve Elledge Lab at Harvard Medical School, where he studied the cellular mechanism responsible for sensing DNA damage and promoting its repair in human cells. Lior brings extensive experience in development and implementation of high resolution as well as screen-oriented assays for DNA repair, including homologous recombination, non-homologous end joining, protein stability, protein localization and small molecule inhibitor sensitization to DNA damage.

Rachel Diamant

VP Intellectual Property & Strategy

Rachel has extensive experience in constructing IP strategy that is designed to serve business objectives, based on careful competitive landscaping, in order to reduce risks and maximize value. Rachel served as IP Director of the technology transfer company of Sheba Medical Center, and later as Director of IP in BASE-Investments. She has managed large consulting projects for international entities such as the EPO, OECD, World Bank, UN and global pharmaceutical companies in the area of global IP policy. In the private market, Rachel has provided in-house support for many biotechnology and medical device companies, and accumulated extensive expertise in IP mining, strategic portfolio design, and hands-on portfolio management. Rachel holds an MSc in Neurobiology from the Weizmann Institute of Science, and a Biotechnology Engineering degree from the Technion, Israel Institute of Technology.

Asael Herman, Ph.D


Joined Emendo as Director of Protein Engineering and in April 2017 appointed as our VP of R&D. Dr. Herman has over 20 years of experience in protein engineering and is an expert in the directed molecular evolution approach. Prior to joining Emendo he led the R&D of Smartzyme Biopharma. He formerly was the VP of R&D at Biolojic Design, an antibodies engineering company. Prior to that he served as Head of Enzyme Engineering at Bio Architecture Lab, a start-up synthetic biology and biofuels firm. Dr. Herman holds a PhD in Bio chemistry and Molecular Biology from the Hebrew University and further trained in protein engineering with Prof. Dan Tawfik at the Weizmann Institute and Prof. Larry Loeb at the University of Washington.

Rafi Emmanuel, Ph.D.

Research Director

Has over 10 years of research experience in the field of transcription and translation regulation of genes, holds a PhD in molecular biology from the Weizmann Institute of Science, Israel. The research was conducted under the supervision of Prof. Rivka Dikstein. Completed his postdoctoral training at Tel Aviv University at Prof. Dan Peer ‘s laboratory where he developed liposomes-based vehicles for targeted delivery of siRNAs and small molecules. Prior to joining Emendo, he was a senior intern at the Weizmann Institute of Science at the laboratory of Prof. Yardena Samuels, where he established tools for homologous recombination-mediated endogenous epitope tagging using rAAV constructs for studying the function of driver mutations in melanoma. Rafi brings broad experience in the development of constructs for improved gene expression and in the use of viral- and liposomes-based systems for the delivery of nucleic acids.

Noam Diamant, Ph.D.

Scientific Advisory Board Member

Noam Diamant is biomed professional combining strong academic background with industry R&D experience and deep understanding of intellectual property. Noam received his Ph.D. in the field of DNA damage repair from the Weizmann institute of Science in 2008. His academic research was published in high profile peer-reviewed journals.

David Dale, MD, UW

Scientific Advisory Board Member

David Dale, M.D., is a board certified physician at the Internal Medicine Center at UWMC-Roosevelt, a UW Professor of General Internal Medicine and former dean of the UW School of Medicine. Dr. Dale earned his M.D. at Harvard. His research interests are focused on susceptibility to infections, neutropenia and regulation of hematopoiesis. His clinical interests include general internal medicine, disorders leading to susceptibility to infections, infectious diseases and hematological disorders and causes, consequences and treatment of neutropenia.

Harry Malech, MD, NIH

Scientific Advisory Board Member

Dr. Malech received his medical degree from Yale University in New Haven, Connecticut, in 1972. He completed clinical residency training at the University of Pennsylvania in Philadelphia, followed by basic research postdoctoral fellowship training at the National Institutes of Health (NIH) in Bethesda, Maryland. After then completing clinical fellowship training in infectious diseases at Yale University, he remained at Yale as assistant and then associate professor until 1986. In 1986, he returned to NIH as a senior investigator in NIAID. He is currently chief of the Laboratory of Host Defenses (LHD). Dr. Malech’s research and clinical program within LHD is the Genetic Immunotherapy Section (GIS).

Andrew Kung, MD, PhD, MSKCC

Scientific Advisory Board Member

Dr. Kung, MD, PhD is a physician-scientist and Chair of the Department of Pediatrics at Memorial Sloan Kettering. He oversees the clinical, research, and educational missions of the department. As a physician, he specializes in caring for patients using cancer genomics, precision medicine, and stem cell transplantation. In his research, he focuses on identifying the causes of pediatric cancers and developing new treatments to benefit children and teens with cancer.